Login / Signup

Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.

Mohammad Ebad Ur RehmanAsmi ChattarajKarun NeupaneAbdul RafaeSajeel SaeedJawad BasitAtif IbrahimJack KhouriSudipto MukherjeeFaiz Anwar
Published in: European journal of haematology (2022)
Results from a randomized controlled trial and an extension study highlighted the efficacy and long-term safety of siltuximab for iMCD; other trials showed tocilizumab to be a suitable alternative. A recent trial reported high response rates with thalidomide in iMCD patients. Promising results were reported for bortezomib in relapsed/ refractory MCD. For human herpesvirus-8 (HHV8)-associated MCD, rituximab along with doxorubicin therapy followed by maintenance with zidovudine and valganciclovir is the most effective therapy. A single-arm trial has highlighted the potential role of tocilizumab in HHV8-MCD. Data for these regimens are limited and mostly comprise nonrandomized trials. Further research on emerging agents could have a major impact on the treatment of this rare disease.
Keyphrases